Amgen Invites Applications for Competitive Grant Program in Bone Research

The Amgen Competitive Grant Program in Bone Research supports innovative research focused on improving the quality of osteoporosis care and patient outcomes.

Specific areas of research eligible for funding through the program include longitudinal data describing long-term (5+ years) osteoporosis care relative to the diverse guidelines; effectiveness of post-fracture care programs demonstrated at a regional or global level (e.g., successfully implemented approaches and techniques, cost savings realized); delivery of optimal care for osteoporosis in the primary care setting (e.g., patient/physician dialogue, patient disease education, disease recognition); impact of osteoporosis on patient quality of life, including loss of independence; health system interventions to improve screening rates in high-risk osteoporosis patients; novel tools and approaches beyond bone-density scanning (dual X-ray absorptiometry) to identify high-risk osteoporosis patients; and solutions to improve patient adherence to their osteoporosis care regimen (e.g., ways to recognize and correct non-compliance).

Grants of up to $150,000 will be awarded through the program.

To be eligible, principal investigators should hold a doctoral degree (e.g. MD, PhD, or PharmD) and have an academic or institutional appointment. Both established and junior investigators may apply, although junior investigators should be within five years of completing their training (instructors, assistant professors, interns, residents, fellows, healthcare professionals) and should provide a letter of recommendation from their department or laboratory head. Proposals are welcomed from investigators and institutions from around the world, with the exception of countries currently subject to sanctions by the United States.

See the Amgen Competitive Grant Program in Bone Research website for complete program guidelines and application instructions.

VIEW ANOTHER RFP RELATED TO MEDICAL RESEARCH

Deadline: June 03, 2019